Methods of using antibodies to detect folate receptor 1 (FOLR1)
The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
1. A method of detecting Folate receptor 1 (FOLR1) expression in a sample comprising contacting said sample with (i) an antibody or antigen-binding fragment thereof that specifically binds to the same FOLR1 epitope as an antibody
comprising the polypeptide of SEQ ID NO:27 and the polypeptide of SEQ ID NO:28; or
(ii) an antibody or antigen-binding fragment thereof that (a) specifically binds to an epitope of FOLR1 comprising an N-glycosylated amino acid and (b) competitively inhibits binding to FOLR1 of an antibody comprising the polypeptide of SEQ ID NO:27 and the polypeptide of SEQ ID NO:28.
2. The method of claim 1 wherein said sample is contacted with an antibody or antigen-binding fragment thereof comprising the variable heavy chain (VH) complementary determining region (CDR)1-3 and variable light chain (VL) CDR1-3 polypeptide sequences selected from the group consisting of:
(a) SEQ ID NOs:3-8, respectively;
(b) SEQ ID NOs:9-14, respectively;
(c) SEQ ID NOs:15-20, respectively;
(d) SEQ ID NOs:21-26, respectively;
(e) SEQ ID NOs: 3-5 and SEQ ID NOs: 59, 7, and 8, respectively;
(f) SEQ ID NOs: 3, 60, and 5 and SEQ ID NOs: 6-8, respectively;
(g) SEQ ID NOs: 3, 61, and 5 and SEQ ID NOs: 6-8, respectively;
(h) SEQ ID NOs: 3, 60, and 5 and SEQ ID NOs: 59, 7, and 8, respectively; and
(i) SEQ ID NOs: 3, 61, and 5 and SEQ ID NOs: 59, 7, and 8, respectively.
3. The method of claim 2 , wherein the detecting is by immunohistochemistry (IHC).
4. The method of claim 2 , wherein the detecting is by enzyme linked immunosorbent assay (ELISA).
5. The method of claim 2 , wherein the antibody or antigen-binding fragment thereof comprises:
(a) a heavy chain variable region (VH) comprising the amino acid sequence of the polypeptide of SEQ ID NO:27 and a light chain variable region (VL) comprising the amino acid sequence the polypeptide of SEQ ID NO:28;
(b) a heavy chain variable region (VH) comprising the amino acid sequence of the polypeptide of SEQ ID NO:29 and a light chain variable region (VL) comprising the amino acid sequence the polypeptide of SEQ ID NO:30;
(c) a heavy chain variable region (VH) comprising the amino acid sequence of the polypeptide of SEQ ID NO:31 and a light chain variable region (VL) comprising the amino acid sequence the polypeptide of SEQ ID NO:32;
(d) a heavy chain variable region (VH) comprising the amino acid sequence of the polypeptide of SEQ ID NO:62 and a light chain variable region (VL) comprising the amino acid sequence the polypeptide of SEQ ID NO:63 or SEQ ID NO:64; or
(e) a heavy chain variable region (VH) comprising the amino acid sequence of the polypeptide of SEQ ID NO:65 and a light chain variable region (VL) comprising the amino acid sequence the polypeptide of SEQ ID NO:66 or SEQ ID NO:67.
6. The method of claim 2 , wherein the antibody or antigen-binding fragment thereof comprises:
(a) a heavy chain comprising the amino acid sequence of SEQ ID NO:33 and a light chain comprising the amino acid sequence of SEQ ID NO:34;
(b) a heavy chain comprising the amino acid sequence of SEQ ID NO:35 and a light chain comprising the amino acid sequence of SEQ ID NO:36; or
(c) a heavy chain comprising the amino acid sequence of SEQ ID NO:37 and a light chain comprising the amino acid sequence of SEQ ID NO:38.
7. The method of claim 3 , wherein the sample is a cancer sample.
8. The method of claim 7 , wherein a FOLR1 score of at least 2 in 25% or greater of the cells identifies the cancer as likely to respond to an active agent comprising an anti-FOLR1 antibody or antigen-binding fragment thereof or indicates that the patient will benefit from administration of an active agent comprising an anti-FOLR1 antibody or antigen-binding fragment thereof.
9. The method of claim 7 , wherein a FOLR1 score of at least 2 in 25% to 75% of the cells identifies the cancer as likely to respond to an active agent comprising an anti-FOLR1 antibody or antigen-binding fragment thereof or indicates that the patient will benefit from administration of an active agent comprising an anti-FOLR1 antibody or antigen-binding fragment thereof.
10. The method of claim 7 , wherein a FOLR1 score of at least 2 in greater than 75% of the cells identifies the cancer as likely to respond to an active agent comprising an anti-FOLR1 antibody or antigen-binding fragment thereof or indicates that the patient will benefit from administration of an active agent comprising an anti-FOLR1 antibody or antigen-binding fragment thereof.
11. The method of claim 7 , wherein a FOLR1 score of at least 3 in 25% or greater of the cells identifies the cancer as likely to respond to an active agent comprising an anti-FOLR1 antibody or antigen-binding fragment thereof or indicates that the patient will benefit from administration of an active agent comprising an anti-FOLR1 antibody or antigen-binding fragment thereof.
12. The method of claim 7 , wherein a FOLR1 score of at least 3 in 25% to 75% of the cells identifies the cancer as likely to respond to an active agent comprising an anti-FOLR1 antibody or antigen-binding fragment thereof or indicates that the patient will benefit from administration of an active agent comprising an anti-FOLR1 antibody or antigen-binding fragment thereof.
13. The method of claim 7 , wherein a FOLR1 score of at least 3 in greater than 75% of the cells identifies the cancer as likely to respond to an active agent comprising an anti-FOLR1 antibody or antigen-binding fragment thereof or indicates that the patient will benefit from administration of an active agent comprising an anti-FOLR1 antibody or antigen-binding fragment thereof.
14. The method of claim 7 , wherein the cancer sample is a bodily fluid, cell, or tissue sample.
15. The method of claim 14 , wherein said bodily fluid is blood, ascites, urine, plasma, serum, or peripheral blood.
16. The method of claim 7 , wherein said cancer is selected from the group consisting of cervical cancer, ovarian cancer, brain cancer, breast cancer, uterine cancer, endometrial cancer, pancreatic cancer, renal cancer, lung cancer, and cancer of the peritoneum.
17. The method of claim 16 , wherein the ovarian cancer is epithelial ovarian cancer.
18. The method of claim 16 , wherein the cancer is platinum resistant, relapsed, or refractory.
19. The method of claim 2 , wherein the antibody or antigen-binding fragment thereof is chimeric or humanized.
20. The method of claim 2 , wherein the antibody or antigen-binding fragment thereof is a full-length antibody.
21. The method of claim 2 , wherein the antibody or antigen-binding fragment thereof is an antigen-binding fragment.
22. The method of claim 2 , wherein the antibody or antigen-binding fragment thereof binds to a human folate receptor 1 with a Kd of about 0.5 to about 10 nM.
23. The method of claim 2 , wherein the antibody or antigen-binding fragment thereof further comprises a detectable label.
24. The method of claim 23 , wherein said detectable label is selected from the group consisting of immunofluorescent label, chemiluminescent label, phosphorescent label, enzyme label, radiolabel, luminophore, avidin/biotin, colloidal gold particles, colored particles, and magnetic particles.
25. The method of claim 23 , wherein said detectable label is selected from the group consisting of biotin, digoxigenin, fluorescein, tritium, and rhodamine.